Trial · NCT01003301
The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
NCT01003301, Phase 2, Completed, Johns Hopkins University; results first posted 2014-04-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge. Trials, record NCT01003301. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01003301
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
- NCT number
- NCT01003301
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 19 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Cat Allergy
- Interventions
- Omalizumab, Placebo
- First posted
- 2009-10-28
- Last updated
- 2014-04-07
- Results first posted
- 2014-04-07
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The the Size of the 8 Late-phase Skin Response | Baseline, 2-6 wks | Reduction in skin late phase size at 8 hours at the time of blood basophil hypo-responsiveness to allergen will be reduced compared to baseline. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The the Size of the 8 Late-phase Skin Response | Baseline, 2-6 wks | percentage decline from NAC-1 | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The the Size of the 8 Late-phase Skin Response | Omalizumab | 54 | Standard Deviation 4 | percentage decline from NAC-1 | |
| The the Size of the 8 Late-phase Skin Response | Placebo | 0 | Standard Deviation 5 | percentage decline from NAC-1 |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Omalizumab | 10 | |
| Overall Study | STARTED | Placebo | 9 | |
| Overall Study | COMPLETED | Omalizumab | 10 | |
| Overall Study | COMPLETED | Placebo | 9 | |
| Overall Study | NOT COMPLETED | Omalizumab | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Omalizumab | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Omalizumab | 0 | 10 |
| Total, other adverse events | Placebo | 0 | 9 |
| Total, serious adverse events | Omalizumab | 0 | 10 |
| Total, serious adverse events | Placebo | 0 | 9 |
Source ClinicalTrials.gov
Papers30
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U19AI070345 | Efficacy of IgE in Mediating Allergic Reactions in Vivo | MACGLASHAN, DONALD W | JOHNS HOPKINS UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 2006 to 2010 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Omalizumab vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01003301
GET https://conductscience.org/api/trials/v1/NCT01003301/papers?page=2